Cancer Blood Tests Compared: What Each Type Can and Cannot Detect
No single blood test screens for all cancer. This guide compares the four kinds of blood test used around cancer, multi-cancer tests, colorectal blood tests and PSA, tumor markers, and routine labs, on what each is for, its evidence, what it misses, what it costs and what a result leads to.
- Published
- November 19, 2026
- Read time
- 14 min read
- Medically reviewed by
-
Rhonda Collins, FNP-C
No single blood test can screen you for cancer in general. The blood tests used around cancer fall into four groups that answer different questions: multi-cancer early detection (MCED) tests, blood tests that screen for one cancer, tumor markers, and routine labs. MCED tests look across many cancers at once, but they miss a large share of cancers and do not replace standard screening [1]. Colorectal blood tests and PSA screen for one cancer each. Tumor markers such as CEA and CA-125 help diagnose and track a known cancer, and they do not work well for screening [2]. Routine labs such as a complete blood count can raise a question but do not diagnose cancer. This guide compares the four on evidence, limits, cost and the follow-up a result needs. Prices were checked on November 19, 2026.
The short answer
- No blood test replaces guideline screening. Mammography, cervical screening, colorectal screening, low-dose CT for people who qualify, and PSA screening remain the tests with guideline support [3].
- MCED tests add to screening. Galleri, LucenceINSIGHT and Cancerguard look for cancer signals in blood. None is FDA approved as of November 2026, and none has been shown to reduce cancer deaths [1][4].
- Two blood tests screen for colorectal cancer. Shield and SimpleScreen CRC are FDA approved for average-risk adults 45 and older, and a positive result needs a colonoscopy [5][6].
- PSA is the one routine blood test used for prostate cancer screening. Guidelines differ on how strongly to recommend it [7][8].
- Tumor markers and routine labs are not screening tests. They help diagnose and monitor, or they hint that something needs a closer look [2].
Cancer blood tests compared at a glance
| Type | Examples | What it is for | What it misses | Next step after an abnormal result |
|---|---|---|---|---|
| Multi-cancer early detection | Galleri, LucenceINSIGHT, Cancerguard | Adding a look at many cancers, most with no routine screening test | Many early cancers; Galleri found 39.3% of cancers diagnosed within a year in PATHFINDER 2 [9] | Diagnostic workup, often imaging guided by the predicted origin |
| Single-cancer screening | Shield, SimpleScreen CRC, PSA | Screening for one cancer in a defined age group | Colorectal blood tests find about 1 in 8 advanced precancerous polyps [10][11] | Colonoscopy for colorectal tests; repeat PSA, MRI or biopsy for PSA |
| Tumor markers | CEA, CA-125, AFP | Helping diagnose a cancer and tracking a known one | Many cancers, especially early ones; rises in benign conditions [2] | Interpretation alongside imaging and history, not a diagnosis on its own |
| Routine labs | CBC, ferritin, calcium | General health; can show effects some cancers cause | Most cancers leave routine labs normal | Finding the cause, which is usually not cancer |
Multi-cancer early detection tests
A multi-cancer early detection test looks for fragments of tumor DNA in the bloodstream that are shared by many cancer types. When it finds a signal, it usually predicts where in the body the signal came from, so the diagnostic workup can start in the right place.
The three MCED tests available in the US work in different ways:
- Galleri (GRAIL) reads DNA methylation patterns and looks for a signal GRAIL reports is shared by more than 50 cancer types [12]. It is one fixed test.
- LucenceINSIGHT (Lucence) comes as panels of named cancers. The Core panel covers 6 cancers, Me adds cancers chosen with your doctor, and 12 covers 12.
- Cancerguard (Exact Sciences) combines DNA and protein markers. Exact Sciences says it helps detect more than 50 cancer types and subtypes, for adults 50 to 84 with no cancer diagnosis in the past 3 years [13].
What the evidence shows
The largest published US study of an MCED test is PATHFINDER 2, which tested Galleri in 32,007 adults aged 50 or older with no suspected cancer [9]:
- Detection: Galleri found 39.3% of the cancers diagnosed in the year after the test, and 69.8% within a prespecified group of 12 cancers.
- False alarms: specificity was 99.64%, so few people without cancer tested positive.
- Positive results: 60.3% of people with a positive result were diagnosed with cancer, which means about 4 in 10 positives were not followed by a cancer diagnosis.
Cancerguard’s published figures come from case-control studies, which compare people already known to have cancer with people known not to. In its independent validation, sensitivity was 55.6% and specificity was 97.4%, and Exact Sciences notes that real-world sensitivity may be lower [13]. Figures from case-control studies and from a screening study like PATHFINDER 2 are not directly comparable. The Galleri vs. LucenceINSIGHT comparison covers the two tests Mito offers in more depth.
What MCED tests do not do
MCED tests do not replace standard screening. The American Cancer Society (ACS) states that “MCD tests do not replace current screening tests,” and that a negative result “might give a false sense of security” [1]. Keep up with mammography, cervical screening, colorectal screening, low-dose CT lung screening if you qualify, and PSA screening as your guidelines advise [3].
Other limits matter too:
- No test is FDA approved yet. An FDA advisory panel voted in favor of Galleri in September 2026, and GRAIL expects the FDA’s decision by early 2027 [4]. Cancerguard has not been cleared or approved by the FDA either [13].
- No mortality benefit has been shown. No study has yet shown that screening with an MCED test reduces cancer deaths, and no US screening guideline includes one [1].
- A negative result does not mean no cancer. Sensitivity is lowest for early-stage cancers, and some cancers shed little DNA into the blood.
- They do not measure inherited risk. An MCED result says nothing about genes such as BRCA1 or BRCA2.
For who each test fits and how to read a result, see the multi-cancer early detection test guide and the MCED explainer.
Single-cancer screening blood tests
Two kinds of blood test screen for one specific cancer: colorectal cancer blood tests and the PSA test for prostate cancer.
Colorectal cancer blood tests: Shield and SimpleScreen CRC
The FDA has approved two blood tests for colorectal cancer screening in adults 45 and older at average risk: Guardant Health’s Shield, approved in July 2024, and Freenome’s SimpleScreen CRC, approved in July 2026 [5][6]. Their labels say a positive result should be followed by colonoscopy, and that neither test replaces a diagnostic colonoscopy or surveillance colonoscopy in high-risk people [5][6].
In their pivotal studies, the tests found most colorectal cancers but few advanced precancerous polyps:
| Test | Study | Cancers detected | Advanced precancerous lesions detected |
|---|---|---|---|
| Shield | ECLIPSE, 7,861 adults [10] | 83.1% | 13.2% |
| SimpleScreen CRC | PREEMPT CRC, 27,010 adults [11] | 79.2% | 12.5% |
Because they miss most precancerous polyps, the ACS lists blood tests as a non-preferred option for people who will not do a stool test or a visual exam such as colonoscopy [14]. The colon cancer blood test guide compares them with FIT, stool DNA tests and colonoscopy.
PSA for prostate cancer
The prostate-specific antigen (PSA) test is the only routine blood test used to screen for a specific cancer. A high PSA can come from prostate cancer, but also from an enlarged prostate, prostatitis, recent ejaculation or vigorous exercise such as cycling [15].
Guidelines differ on how strongly to recommend PSA screening:
- ACS (updated November 2026): men at average risk should have a PSA test every 2 years from 50 through 69. Black men and men with a close relative diagnosed with prostate cancer should start at 45 [7].
- US Preventive Services Task Force (USPSTF, 2018): for men 55 to 69, the decision to be screened should be an individual one, and it recommends against PSA screening from age 70. The USPSTF is updating this recommendation [8].
The main harm of PSA screening is overdiagnosis: finding prostate cancers that would never have caused problems, whose treatment can cause urinary, bowel and sexual side effects [15]. The normal PSA levels by age guide explains how results are read.
Tumor markers: CEA, CA-125 and AFP
Tumor markers are substances that some cancers make in larger amounts. They help diagnose a cancer alongside imaging and biopsy, and they track how a known cancer responds to treatment. They are not screening tests. The National Cancer Institute (NCI) says studies “have generally found that these markers do not work well for screening,” because they miss many cancers and can be raised in people who do not have cancer [2].
| Marker | Cancers it is linked to | How it is used [16] |
|---|---|---|
| CEA | Colorectal and some other cancers | To check the effect of treatment and detect recurrence |
| CA-125 | Ovarian cancer | To help in diagnosis, assess response to treatment and evaluate recurrence |
| AFP | Liver cancer, ovarian cancer and germ cell tumors | To help diagnose these cancers and follow response to treatment |
Two examples show why a marker alone does not screen:
- CA-125 for ovarian cancer. The USPSTF recommends against screening for ovarian cancer in women without symptoms who do not have a known high-risk hereditary syndrome. Trials of CA-125 and transvaginal ultrasound found no screening approach that reduced ovarian cancer deaths, and false positives led to unnecessary surgery [17].
- CEA for colorectal cancer. Smoking and several noncancerous conditions raise CEA, and many early cancers do not, so it is not used to screen for or diagnose cancer [18].
Marker tests still have a place for people with a reason to track them, such as monitoring after treatment with an oncologist. The CEA article, the CA-125 biomarker page and the AFP article cover each marker.
Can routine blood work show cancer?
Routine blood work does not test for cancer, but it can show effects that some cancers cause. A normal result does not rule cancer out, and an abnormal one is far more often explained by something else.
- Complete blood count (CBC). A CBC is used to monitor blood cancers, and a low white cell count can be a sign of a bone marrow disorder or cancer, among other causes such as medicines [19]. A high count is most often from infection or inflammation; see high white blood cell count.
- Hemoglobin and ferritin. Slow bleeding from a colorectal cancer can cause iron deficiency anemia, and the ACS notes that sometimes the first sign of colorectal cancer is a blood test showing a low red blood cell count [20]. Most anemia has other causes; see is low hemoglobin a sign of cancer?
- Calcium. A high calcium level has several causes, one of which is cancer; see is high calcium a sign of cancer?
An unexplained abnormal result is a reason to find its cause with your doctor, not a cancer diagnosis.
How much do cancer blood tests cost?
Prices range from a few dollars for a routine test to more than $1,000 for the broadest multi-cancer panel. The table compares the test price only, without draw fees, order fees or membership fees on either side. Mito prices are member prices for the linked product; membership is $9 per month or $99 per year, and any lab draw fee is itemized before you pay. Seller prices come from each seller’s own page.
| Test | Type | Mito member price | Seller’s own price |
|---|---|---|---|
| Galleri | MCED | $636.12 | $949 list price (GRAIL) [21] |
| LucenceINSIGHT Core | MCED, 6 cancers | $430.92 | Not listed |
| LucenceINSIGHT Me | MCED, 7 to 9 cancers | $754.92 | Not listed |
| LucenceINSIGHT 12 | MCED, 12 cancers | $1,294.92 | Not listed |
| Cancerguard | MCED | Not sold by Mito | $689 self-pay (Exact Sciences) [13] |
| Shield | Colorectal screening | Not sold by Mito | $1,495 cash rate (Guardant Health) [22] |
| PSA, total with reflex to free PSA | Prostate screening | $5.19 | |
| CEA | Tumor marker | $6.87 | |
| CA-125 | Tumor marker | $16.86 | |
| CBC with differential | Routine lab | $2.70 |
Prices checked on November 19, 2026. SimpleScreen CRC is left out because no cash price was listed on Freenome’s or Abbott’s own pages.
Insurance treats these tests differently. Most insurers do not cover MCED tests, and Exact Sciences does not bill insurance for Cancerguard [13][21]. Shield is covered by Medicare: Original Medicare covers an FDA-approved blood-based colorectal screening test once every 3 years for people 45 to 85 at average risk with no symptoms [23], and Guardant says most commercially insured patients pay nothing out of pocket [22]. For the full MCED price breakdown, see multi-cancer blood test cost; for paying with pre-tax funds, see HSA and FSA eligible health tests.
What happens after an abnormal cancer blood test?
A positive or abnormal result on any of these tests is a reason for diagnostic testing, not a diagnosis. What comes next depends on the test:
- Positive MCED result. A diagnostic workup, which may include imaging or tissue sampling directed by the predicted cancer origin. The ACS notes that doctors are still learning which follow-up tests work best [1]. Some people with a positive result are not found to have cancer.
- Positive colorectal blood test. A colonoscopy, which the FDA labels for Shield and SimpleScreen CRC require [5][6].
- Raised PSA. Often a repeat test in 6 to 8 weeks, then continued monitoring, an MRI or a biopsy if it stays high or keeps rising [15].
- Raised tumor marker or abnormal routine lab. A look for the cause, which is usually not cancer, guided by your symptoms and history.
New symptoms deserve attention whatever a blood test says. Screening tests are for people without symptoms, and symptoms call for a diagnostic evaluation instead.
Where Mito fits
Mito sells several of the tests in this guide at member prices, with a clinician reviewing each order and its results:
- Galleri and LucenceINSIGHT for people who want to add a multi-cancer test to their guideline screening.
- PSA for prostate cancer screening.
- CEA and CA-125 for tracking a known cancer, not for screening.
- A CBC as part of routine blood work.
Mito does not sell Shield, SimpleScreen CRC, Cancerguard, stool tests, mammography or colonoscopy. For those, start with your primary care clinician or insurer. The personalized cancer screening plan after 40 shows how age and risk shape which screening you need.
Related reading
- Multi-cancer early detection test guide
- What is a multi-cancer early detection (MCED) test?
- Galleri test accuracy and results
- Colon cancer blood test
- PSA test cost
- Personalized cancer screening plan after 40
References
- American Cancer Society: Multi-cancer Detection (MCD) Tests (revised October 2, 2025)
- National Cancer Institute: Tumor Markers fact sheet
- American Cancer Society: Guidelines for the Early Detection of Cancer (revised November 12, 2026)
- GRAIL: Third Quarter 2026 Financial Results (November 4, 2026)
- US Food and Drug Administration: Premarket Approval P230009, Shield
- US Food and Drug Administration: Premarket Approval P250029, SimpleScreen CRC
- American Cancer Society: Recommendations for Prostate Cancer Early Detection (revised November 12, 2026)
- US Preventive Services Task Force: Prostate Cancer Screening (May 8, 2018)
- Nabavizadeh N et al. Performance and safety of a multi-cancer early detection test: the PATHFINDER 2 study. Nat Med. 2026.
- Chung DC et al. A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening. N Engl J Med. 2024.
- Shaukat A et al. Clinical Validation of a Circulating Tumor DNA-Based Blood Test to Screen for Colorectal Cancer. JAMA. 2025.
- GRAIL: Types of cancer detected by Galleri
- Exact Sciences: Cancerguard resources for healthcare providers
- American Cancer Society: Colorectal Cancer Screening Tests
- National Cancer Institute: Prostate-Specific Antigen (PSA) Test
- National Cancer Institute: Tumor Markers in Common Use
- US Preventive Services Task Force: Ovarian Cancer Screening (February 13, 2018)
- MedlinePlus: CEA Test
- MedlinePlus: Complete Blood Count (CBC)
- American Cancer Society: Colorectal Cancer Signs and Symptoms
- GRAIL: How much does the Galleri test cost?
- Guardant Health: Shield coverage and support
- Medicare.gov: Blood-based biomarker tests for colorectal cancer screening
Frequently asked questions
Can a blood test detect cancer?
Some blood tests can find signs of certain cancers, but no blood test screens for every cancer or rules cancer out. Multi-cancer tests such as Galleri look for cancer DNA from many cancer types at once, and two FDA-approved blood tests screen for colorectal cancer. Each misses a meaningful share of cancers, and any positive result needs diagnostic tests such as imaging, colonoscopy or a biopsy to confirm or rule out cancer.
Will cancer show up in normal blood work?
Usually not. A routine blood count or metabolic panel does not test for cancer. It can show changes that some cancers cause, such as anemia from slow bleeding or abnormal white blood cells in a blood cancer, but those changes have many other causes. A normal result does not rule cancer out, and an abnormal one does not diagnose it.
Do tumor markers like CEA or CA-125 screen for cancer?
No. The National Cancer Institute says tumor markers generally do not work well for screening, because they miss many cancers and can rise in people who do not have cancer. They are used alongside imaging and biopsy to help diagnose a cancer, and to track a cancer that has already been diagnosed. The USPSTF recommends against ovarian cancer screening with CA-125 in women without symptoms or a known hereditary syndrome.
Does a multi-cancer blood test replace mammograms or colonoscopy?
No. The American Cancer Society states that multi-cancer detection tests do not replace current screening tests. Keep up with guideline screening for breast, cervical, colorectal, lung and prostate cancer, and use a multi-cancer test, if at all, as an addition to it.
How much does a cancer blood test cost?
It depends on the type. On November 19, 2026, Galleri had a list price of $949 from GRAIL and a Mito member price of $636.12. Cancerguard was $689 self-pay from Exact Sciences, and the Shield colorectal blood test had a $1,495 cash rate from Guardant Health. Single tumor marker and routine blood tests cost far less, from $2.70 for a CBC to $16.86 for CA-125 at Mito member prices.
What happens after a positive cancer blood test?
A positive screening blood test is not a diagnosis. A positive colorectal blood test should be followed by a colonoscopy. A positive multi-cancer test leads to a diagnostic workup, often imaging directed by the predicted cancer origin. A raised PSA is usually repeated and may lead to an MRI or biopsy. Some people with a positive result turn out not to have cancer.
